环磷腺苷联合参麦注射液治疗老年冠心病慢性心力衰竭的疗效

目的：观察环磷腺苷联合参麦注射液治疗老年冠心病慢性心力衰竭（CHF）的临床疗效。方法：老年冠心病CHF患者126例，随机分为常规治疗组62例，给予常规抗心衰治疗；观察组64例，在常规治疗的基础上静脉滴注环磷腺苷及参麦注射液14d。观察两组治疗前后血浆脑钠肽（BNP）水平、左室射血分数（LVEF），舒张早期／晚期最大血流速度比值（E／A）等指标的变化及临床疗效。结果：治疗后，两组各指标（常规治疗组除E／A外）均有明显改善（P均〈0．01），与常规治疗组比较，观察组总有效率明显提高（77．42％比89．06％，P〈0．01）；LVEVF（44．51±7．85）％比（58．35±7．80）％]，E／A值（0．69±0．35）比（0．88±0．36）]明显改善，BNP浓度明显下降（558．20±79．30）ng／L比（437．10±67．90）ng／L]，6min步行距离明显提高（526．70±12．00）m比（629．20±12．20）m]，P均〈0．01。结论：环磷腺苷联合参麦注射液治疗老年冠心病慢性心力衰竭安全、有效。

Therapeutic effects of adenosine cyclophosphate combined with Shenmai injection on chronic heart failure in aged patients with coronary heart disease

Objective.. To observe the therapeutic effects of adenosine cyclophosphate combined with Shenmai injection on chronic heart failure （CHF） in aged patients with coronary heart disease （CHD）. Methods： A total of 126 aged CHD patients with CHF were randomly divided into routine treatment group （n=62, received routine antiheart failure treatment） and observation group （n= 64, received adenosine cyclophosphate and Shenmai injection intravenous drip for 14d based on routine treatment）. Clinical therapeutic effects and changes of plasma level of brain natriuretic peptide （BNP）, left ventricular ejection fraction （LVEF） and peak early diastolic velocity/peak late diastolic velocity （E/A） were observed and compared between the two groups before and after treatment. Results.. After treatment, all indicators in the two groups significantly improved except for E/A in routine treatment group, P 〈0.01 all. Compared with routine treatment group, there were significant increase in total effective rate （77.42% vs. 89.06%）, LVEFE （44.51±7.85）% vs. （58. 35±7. 80）%], E/AE （0.69±0.35） vs. （0.88±0.36）] , 6 rain walking distance （526.70± 12.00） m vs. （629.20± 12.20） m], and significant decrease in BNP concentration - （558.20±79.30） ng/L vs. （437.10±67.90） ng/L] in observation group, P（0.01 all. Conclusion： Adenosine cyclophosphate combined with Shenmai injection is safe and effective in treatment of chronic heart failure in aged patients with coronary heart disease.